Karyopharm Therapeutics (KPTI) Revenue & Revenue Breakdown
Karyopharm Therapeutics Revenue Highlights
Latest Revenue (Y)
$146.03M
Latest Revenue (Q)
$42.79M
Main Segment (Y)
License and Service
Main Geography (Y)
CANADA
Karyopharm Therapeutics Revenue by Period
Karyopharm Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $146.03M | -7.03% |
| 2022-12-31 | $157.07M | -25.14% |
| 2021-12-31 | $209.82M | 94.12% |
| 2020-12-31 | $108.08M | 164.31% |
| 2019-12-31 | $40.89M | 34.80% |
| 2018-12-31 | $30.34M | 1790.09% |
| 2017-12-31 | $1.60M | 942.21% |
| 2016-12-31 | $154.00K | -38.40% |
| 2015-12-31 | $250.00K | 9.17% |
| 2014-12-31 | $229.00K | -40.83% |
| 2013-12-31 | $387.00K | -38.96% |
| 2012-12-31 | $634.00K | 317.11% |
| 2011-12-31 | $152.00K | - |
Karyopharm Therapeutics generated $146.03M in revenue during NA 2023, up -7.03% compared to the previous quarter, and up 481.39% compared to the same period a year ago.
Karyopharm Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $42.79M | 29.16% |
| 2024-03-31 | $33.13M | -1.84% |
| 2023-12-31 | $33.75M | -6.28% |
| 2023-09-30 | $36.01M | -4.18% |
| 2023-06-30 | $37.58M | -2.89% |
| 2023-03-31 | $38.70M | 15.24% |
| 2022-12-31 | $33.58M | -7.10% |
| 2022-09-30 | $36.15M | -8.91% |
| 2022-06-30 | $39.68M | -16.76% |
| 2022-03-31 | $47.67M | -62.25% |
| 2021-12-31 | $126.27M | 235.03% |
| 2021-09-30 | $37.69M | 66.76% |
| 2021-06-30 | $22.60M | -2.83% |
| 2021-03-31 | $23.26M | -33.73% |
| 2020-12-31 | $35.10M | 64.53% |
| 2020-09-30 | $21.33M | -36.35% |
| 2020-06-30 | $33.51M | 84.77% |
| 2020-03-31 | $18.14M | 0.23% |
| 2019-12-31 | $18.10M | 37.62% |
| 2019-09-30 | $13.15M | 38.51% |
| 2019-06-30 | $9.49M | 6024.52% |
| 2019-03-31 | $155.00K | -24.76% |
| 2018-12-31 | $206.00K | -13.81% |
| 2018-09-30 | $239.00K | -98.80% |
| 2018-06-30 | $19.89M | 98.91% |
| 2018-03-31 | $10.00M | 551.89% |
| 2017-12-31 | $1.53M | 100.00% |
| 2017-09-30 | - | -100.00% |
| 2017-06-30 | $3.00K | -95.59% |
| 2017-03-31 | $68.00K | 44.68% |
| 2016-12-31 | $47.00K | -2.08% |
| 2016-09-30 | $48.00K | -18.64% |
| 2016-06-30 | $59.00K | 100.00% |
| 2016-03-31 | - | -100.00% |
| 2015-12-31 | $25.00K | -66.67% |
| 2015-09-30 | $75.00K | -50.00% |
| 2015-06-30 | $150.00K | 100.00% |
| 2015-03-31 | - | -100.00% |
| 2014-12-31 | $15.00K | -28.57% |
| 2014-09-30 | $21.00K | - |
| 2014-06-30 | $21.00K | -87.72% |
| 2014-03-31 | $171.00K | 714.29% |
| 2013-12-31 | $21.00K | 100.00% |
| 2013-09-30 | - | -100.00% |
| 2013-06-30 | $133.00K | -42.92% |
| 2013-03-31 | $233.00K | 606.06% |
| 2012-12-31 | $33.00K | -2.94% |
| 2012-09-30 | $34.00K | - |
Karyopharm Therapeutics generated $42.79M in revenue during Q2 2024, up 29.16% compared to the previous quarter, and up 110.56% compared to the same period a year ago.
Karyopharm Therapeutics Revenue Breakdown
Karyopharm Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| License and Service | $24.36M | $15.67M | - | - | - |
| Royalty | $1.50M | $300.00K | - | - | - |
| License | $3.50M | - | - | - | - |
| License And Other | - | - | $111.38M | $31.88M | $10.35M |
| Product | - | - | $98.44M | $76.21M | $30.54M |
Karyopharm Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License and Service (82.97%), License (11.92%), and Royalty (5.11%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Health Care, Other | $203.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License and Service | $6.41M | $4.45M | $5.56M | $5.61M | $8.74M | $437.00K | $1.62M | $6.53M | - | - | - | - | - | - | - | - | - | - | - |
| Royalty | - | - | $1.50M | $400.00K | $200.00K | $1.00M | $1.40M | $1.00M | - | - | - | - | - | - | - | - | - | - | - |
| Other Royalty | - | - | $500.00K | $400.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | - | - | - | - | - | - | - | - | $28.30M | $29.80M | $26.72M | $20.18M | $21.73M | $20.22M | $21.33M | $18.60M | $16.06M | $17.72M | $12.82M |
| License And Other | - | - | - | - | - | - | - | - | $19.37M | $96.47M | $10.97M | $2.42M | $1.53M | $14.88M | $3.00K | $14.91M | $2.08M | $377.00K | $328.00K |
Karyopharm Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: License and Service (96.93%), and Health Care, Other (3.07%).
Karyopharm Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 |
|---|---|
| CANADA | $5.00M |
Karyopharm Therapeutics's latest annual revenue breakdown by geography, as of Dec 20: CANADA (100.00%).
Karyopharm Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KPTI | Karyopharm Therapeutics | $146.03M | $42.79M |
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| MRSN | Mersana Therapeutics | $36.85M | $2.29M |
| AGIO | Agios Pharmaceuticals | $26.82M | $8.96M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| BLUE | bluebird bio | $3.60M | $16.10M |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| GOSS | Gossamer Bio | - | $95.84M |
| RLYB | Rallybio | - | $299.00K |
| ABOS | Acumen Pharmaceuticals | - | - |
| REPL | Replimune Group | - | - |
| NLTX | Neurogene | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| NVCT | Nuvectis Pharma | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| NUVB | Nuvation Bio | - | $1.44M |
KPTI Revenue FAQ
What is Karyopharm Therapeutics’s yearly revenue?
Karyopharm Therapeutics's yearly revenue for 2023 was $146.03M, representing a decrease of -7.03% compared to 2022. The company's yearly revenue for 2022 was $157.07M, representing a decrease of -25.14% compared to 2021. KPTI's yearly revenue for 2021 was $209.82M, representing an increase of 94.12% compared to 2020.
What is Karyopharm Therapeutics’s quarterly revenue?
Karyopharm Therapeutics's quarterly revenue for Q2 2024 was $42.79M, a 29.16% increase from the previous quarter (Q1 2024), and a 13.86% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $33.13M, a -1.84% decrease from the previous quarter (Q4 2023), and a -14.40% decrease year-over-year (Q1 2023). KPTI's quarterly revenue for Q4 2023 was $33.75M, a -6.28% decrease from the previous quarter (Q3 2023), and a 0.50% increase year-over-year (Q4 2022).
What is Karyopharm Therapeutics’s revenue growth rate?
Karyopharm Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -30.40%, and for the last 5 years (2019-2023) was 257.11%.
What are Karyopharm Therapeutics’s revenue streams?
Karyopharm Therapeutics's revenue streams in c 23 are License and Service, Royalty, and License. License and Service generated $24.36M in revenue, accounting 82.97% of the company's total revenue, up 55.44% year-over-year. Royalty generated $1.5M in revenue, accounting 5.11% of the company's total revenue, up 400.00% year-over-year. License generated $3.5M in revenue, accounting 11.92% of the company's total revenue
What is Karyopharm Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Karyopharm Therapeutics was License and Service. This segment made a revenue of $24.36M, representing 82.97% of the company's total revenue.